Skip to main content
OpenTrials
Completed

NCT Number: NCT03393260

Epidemiological Characteristics and Prognosis Factors of Cancer Patients Admitted at French Emergency Departments

Patients with cancer or hematological malignancy are susceptible to present acute complications linked to their disease or to their specific treatments (dyspnea, sepsis, coma, hemorrhagic syndrome). Emergency physicians are in first line when these complications arise and have to face with some complex situations in which informations about patient malignancy or prognosis may be lacking. Nowadays, there is very few epidemiological data published concerning how cancer patient use Emergency Departments (EDs) and cancer patient care delivery in the EDs.

Thus, an observational multicenter prospective cross-sectional study is conducted to study the prevalence of cancer patients admitted to French EDs, and to describe the different reasons for cancer patients to seek care in EDs with their prevalence and underscore those linked to cancer or treatment complication

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Patients Disease Attributes Emergencies Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Saint Louis

Paris, 75010, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients (age >=18 years)
  • with active malignancy or a history of cancer in remission within the last 5 years
  • being attended in one of the 400 French emergency centers participating in the study during the 3-day study period

Exclusion criteria

  • opposition to participate

Treatment and study plan

Primary outcomes

  1. Reasons for cancer patients to seek care in EDs

    Time frame: 1 day

Secondary outcomes

  1. cancer location

    Time frame: 1 day

  2. hospitalisation rate

    Time frame: 1 day

  3. intensive care unit (ICU) admission

    Time frame: 7 days

  4. ICU mortality

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: EPICANCER

Important dates

Study start
2018
Primary completion
2018
Study completion
2019
First posted
Jan 8, 2018
Registry last updated
Jan 7, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.